ArticleJournal of oral and maxillofacial pathology : JOMFP
Exploring salivary gland lesions: Unveiling malignancy risks using the Milan classification.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Salivary gland tumours (SGTs) are characterized by exceptional heterogeneity, diversity, and frequent morphological overlap among different entities. Fine needle aspiration cytology (FNAC) plays a pivotal role in evaluating salivary gland lesions (SGLs), facilitating prompt and accurate diagnosis and treatment. The Milan System of Reporting Salivary Gland Cytology (MSRSGC) is a six-tiered reporting system that aims to standardize SG reporting, fostering consistency in clinical management. Aims/Objectives: To assess the cytomorphological patterns of various SGLs and categorize them according to MSRSGC. To study the frequency of SGLs by demographics, evaluate the efficacy of FNAC, and determine the risk of malignancy (ROM) through cyto-histo correlation. Materials and Methods: This descriptive cross-sectional study involved 80 FNAC cases of SGLs sent to the pathology department from January 2018 to September 2022 (five years). Cytological findings were meticulously evaluated, categorized according to the MSRSGC, and correlated with histology wherever available. Observation and Results: Out of a total of 80 cases, 34 were available for histopathological examination. The predominant age group affected was 51-60 years (23.75%) and the male-to-female ratio was 1.9:1. The parotid gland was most commonly involved (69%), followed by the submandibular gland (26%) and the minor salivary gland (5%). The frequency of case distribution according to MSRSGC in Categories I, II, III, IVA, IVB, V, and VI was 8%, 11%, 5%, 53%, 16%, 3%, and 5%, respectively. The ROM reported for each category was 0%, 0%, --, 6.25%, 40%, 100%, and 100%, respectively. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were of 80%, 100%, 100%, 94.44%, and 95.45%, respectively, underscoring its clinical utility. Among the available histological follow-up cases, maximum cases were available in Category IVB (77%), followed by Category VI (75%). Conclusion: FNAC proves to be a reliable diagnostic tool for SGLs, despite the inherent challenges of heterogeneity. Employing the MSRSGC enhances diagnostic precision, mitigating the risk of false positives and false negatives, thereby improving clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.